bezlotoxumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
bezlotoxumab

GtoPdb Ligand ID: 13334

Synonyms: BLA 761046 | MBL-CDB1 | MDX-1388 | Zinplava®

bezlotoxumab is an approved drug (FDA (2016), EMA (2017), Japan (2017))

Compound class: Antibody

Comment: Bezlotoxumab is a fully human IgG1 monoclonal antibody that binds to Clostridioides difficile toxin B [1]. It does not have inherent antibacterial activity but prevents binding of toxin B to colonic cells and reducing colonic cell inflammation. It is used to reduce the recurrence of C. difficile infection (CDI) in patients receiving antibacterial treatment for CDI.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

References
1. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D et al.. (2006) Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun, 74 (11): 6339-47. [PMID:16966409]

References

1. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D et al.. (2006)
Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.
Infect Immun, 74 (11): 6339-47. [PMID:16966409]